Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in which Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
October 2024—Qiagen has released a new version of its clinical decision support software Qiagen Clinical Insight Interpret. The latest release builds on the advanced artificial intelligence capabilities of QCI Interpret, including AI-derived literature searches and AI-trained phenotype-driven ranking.
October 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. The Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options, and enable full use of all common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright dyes, reduces spillover and spreading to provide high-resolution data.
October 2024—Roche announced the launch of the Cobas Respiratory flex test, the first to use Roche’s novel and proprietary TAGS (temperature-activated generation of signal) technology. Developed by Roche scientists, TAGS technology uses multiplex PCR testing combined with color, temperature, and data processing to identify as many as 15 pathogens in a single PCR test. The Respiratory flex test can detect up to 12 of the most common respiratory viruses, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2. The test runs on the high-throughput Cobas 5800, 6800, and 8800 analyzers.
October 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory trial.
October 2024—Maine Molecular Quality Controls now offers Spotfire RSP Controls for the Biofire Spotfire Respiratory/Sore Throat Panel Mini assay. The controls are intended for use as an external assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of pathogens on all Biofire Spotfire respiratory assays performed on the Spotfire system. The kit contains six positive and six negative controls in 300-µL tubes. Maine Molecular Quality Controls 207-885-1072
October 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla. The theme for Pathology Visions 2024 is “Decision Digital.”
Oct. 9, 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia.
Oct. 8, 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al.
Oct. 7, 2024—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow in a single instrument.
